Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Comparison of Effects of Standard Dose vs. Low Dose Advagraf With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response

Trial Profile

A Comparison of Effects of Standard Dose vs. Low Dose Advagraf With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary) ; Basiliximab; Corticosteroids; Corticosteroids; Irbesartan; Methylprednisolone; Mycophenolate mofetil; Prednisone; Ramipril
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Registrational
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 23 Dec 2018 Primary endpoint has not been met. (The prevalence of IF/TA (defined as ci+ct2) at Month 24 (in the ACEi/ARB vs OAHT intervention groups).), as reported in ab article published in the American Journal of Transplantation.
    • 23 Dec 2018 Primary endpoint has not been met. (The incidence of allograft interstitial fibrosis and tubular atrophy (IF/TA) as assessed at a central pathology lab), as reported in ab article published in the American Journal of Transplantation.
    • 23 Dec 2018 Results published in the American Journal of Transplantation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top